ArticleCancer immunology research2015
Mass cytometry analysis shows that a novel memory phenotype B cell is expanded in multiple myeloma.
Article in Cancer immunology research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 44 citations in OpenAlex.
- Lymphocyte profile in peripheral blood of patients with multiple myeloma.Annals of hematology · 2024Article
- Characterization of Human B Cell Hematological Malignancies Using Protein-Based Approaches.International journal of molecular sciences · 2024Review
- Review
- Immune Phenotypes and Target Antigens of Clonally Expanded Bone Marrow T Cells in Treatment-Naïve Multiple Myeloma.Cancer immunology research · 2022Article
- Prolonged viral shedding of SARS-CoV-2 in two immunocompromised patients, a case report.BMC infectious diseases · 2021Article
- Deep profiling of apoptotic pathways with mass cytometry identifies a synergistic drug combination for killing myeloma cells.Cell death and differentiation · 2020Article
- Unraveling the Complexity of the Cancer Microenvironment With Multidimensional Genomic and Cytometric Technologies.Frontiers in oncology · 2020Review
- Review
- Mixed-effects association of single cells identifies an expanded effector CD4Science translational medicine · 2018Article
- Circulating plasmablasts are elevated and produce pathogenic anti-endothelial cell autoantibodies in idiopathic pulmonary arterial hypertension.European journal of immunology · 2018Article
- Integrated functional and mass spectrometry-based flow cytometric phenotyping to describe the immune microenvironment in acute myeloid leukemia.Journal of immunological methods · 2018Article
- Robust B Cell Responses Predict Rapid Resolution of Lyme Disease.Frontiers in immunology · 2018Article
- Clonal Expansion and Interrelatedness of Distinct B-Lineage Compartments in Multiple Myeloma Bone Marrow.Cancer immunology research · 2017Article
- Mass cytometry deep phenotyping of human mononuclear phagocytes and myeloid-derived suppressor cells from human blood and bone marrow.Journal of leukocyte biology · 2017Article
- Regulatory myeloid cells: an underexplored continent in B-cell lymphomas.Cancer immunology, immunotherapy : CII · 2017Review
- Testing for differential abundance in mass cytometry data.Nature methods · 2017Article
- Systems immune monitoring in cancer therapy.European journal of cancer (Oxford, England : 1990) · 2016Review
- Immunocapture strategies in translational proteomics.Expert review of proteomics · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
Abstract
It would be very beneficial if the status of cancers could be determined from a blood specimen. However, peripheral blood leukocytes are very heterogeneous between individuals, and thus high-resolution technologies are likely required. We used cytometry by time-of-flight and next-generation sequencing to ask whether a plasma cell cancer (multiple myeloma) and related precancerous states had any consistent effect on the peripheral blood mononuclear cell phenotypes of patients. Analysis of peripheral blood samples from 13 cancer patients, 9 precancer patients, and 9 healthy individuals revealed significant differences in the frequencies of the T-cell, B-cell, and natural killer-cell compartments. Most strikingly, we identified a novel B-cell population that normally accounts for 4.0% ± 0.7% (mean ± SD) of total B cells and is up to 13-fold expanded in multiple myeloma patients with active disease. This population expressed markers previously associated with both memory (CD27(+)) and naïve (CD24(lo)CD38(+)) phenotypes. Single-cell immunoglobulin gene sequencing showed polyclonality, indicating that these cells are not precursors to the myeloma, and somatic mutations, a characteristic of memory cells. SYK, ERK, and p38 phosphorylation responses, and the fact that most of these cells expressed isotypes other than IgM or IgD, confirmed the memory character of this population, defining it as a novel type of memory B cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.